Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors

Costanzi, John J.; Coltman, Charles A.; Col, Lt

doi:10.1002/1097-0142(196903)23:3<589::aid-cncr2820230310>3.0.co;2-a

Cited by 57 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined agent therapy A 5 day cyclical regime of quadruple therapy was used (Costanzi & Coltman, 1969;Hanham, Newton & Westbury, 1971) The other three cytotoxic drugs were administered intravenously as described for 5FU. An intravenous dose of metoclopramide preceded each course of cytotoxic therapy throughout the study.…”

Section: Chemotherapy Schedulesmentioning

confidence: 99%

Plasma levels of 5‐fluorouracil after oral and intravenous administration in cancer patients.

Finch¹,

Bending²,

Lant³

1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. Plasma levels of 5‐fluorouracil (5FU) have been determined in eleven cancer patients after 0.5 g and 1.0 g intravenous doses, and in one patient after paired 1.0 g oral and intravenous doses. 2. The plasma half‐life after the 0.5 g intravenous dose was relatively constant, irrespective of the stage and spread of the disease. 3. Plasma kinetics of the drug were dose dependent. Doubling of the intravenous dose produced a 1.5‐fold increase in plasma half life, a two‐fold increase in initial plasma drug concentration, and a three‐fold increase in area under the concentration/time curve. 4. In one patient receiving paired 1.0 g intravenous and oral doses nine weeks apart, an increase in the bioavailability of the drug coincided with a marked clinical regression in palpable intra‐abdominal metastases. 5. The significance of measuring plasma drug kinetics and their relationship to drug efficacy and toxicity are discussed.

show abstract

Section: Chemotherapy Schedulesmentioning

confidence: 99%

Plasma levels of 5‐fluorouracil after oral and intravenous administration in cancer patients.

Finch¹,

Bending²,

Lant³

1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In 1971 Hanham, Newton and Westbury reported on 75 cases treated with quadruple chemotherapy using a modification of the regimen devised by Costanzi and Coltman (1969). We have continued to use this regimen and this report concerns those patients in the first 150 treated by quadruple chemotherapy who had hepatic metastases.…”

Section: Chemotherapeutic Regimenmentioning

confidence: 99%

“…The method requires no specialized equipment as neither grossly deranged liver enzymes nor jaundice are contra-indications to treatment, and toxicity is easily monitored and readily controlled. CHEMOTHERAPEUTIC REGIMEN In 1971 Hanham, Newton and Westbury reported on 75 cases treated with quadruple chemotherapy using a modification of the regimen devised by Costanzi and Coltman (1969). We have continued to use this regimen and this report concerns those patients in the first 150 treated by quadruple chemotherapy who had hepatic metastases.…”

mentioning

confidence: 99%

Results of 27 Cases with Hepatic Metastases Treated by Combination Chemotherapy

Priestman¹,

Hanham²

1972

Br J Cancer

View full text Add to dashboard Cite

Summary.-The results of using a standard combination of cytotoxic agents in 27 cases of secondary liver cancer are reported. A brief review of the methods available for treating hepatic metastases from solid tumours, as opposed to lymphomata, is included. The response rate depends on the site of the primary lesion. It is suggested that in patients with mammary or colorectal primary tumours, combination chemotherapy represents an advance in treatment with an objective response rate of 730/% and 66% respectively in the 2 groups. The method requires no specialized equipment as neither grossly deranged liver enzymes nor jaundice are contra-indications to treatment, and toxicity is easily monitored and readily controlled. CHEMOTHERAPEUTIC REGIMENIn 1971 Hanham, Newton and Westbury reported on 75 cases treated with quadruple chemotherapy using a modification of the regimen devised by Costanzi and Coltman (1969). We have continued to use this regimen and this report concerns those patients in the first 150 treated by quadruple chemotherapy who had hepatic metastases.Liver biopsy is not performed as a routine on patients suspected of having metastases, thus antemortem histological confirmation of liver involvement was not always available. Hepatic metastases were therefore diagnosed when 3 or more of the following were present: (1) Hepatomegaly; (2) raised alkaline phosphatase level; (3) raised aspartate aminotransferase (SGOT) level; (4) evidence of hepatic metastases on gamma scan.Of the 150 patients reviewed, 27 had hepatic metastases on these criteria. This figure is lower than might be expected and this is largely explained by the high proportion of head and neck cancers.

show abstract

“…The development of combination regimens of chemotherapy has allowed more effective treatment of some solid tumours without unacceptable toxic side-effects. At this hospital considerable experience has now been gained in the treatment of solid tumours using one such regimen (Hanham, Newton & Westbury, 1971). This report concerns seven consecutive patients who presented with jaundice due to metastases from various malignant tumours, and who were treated with quadruple chemotherapy.…”

Section: Introductionmentioning

confidence: 99%